WeightLossSteroidsWhiteAntiAgingPharmaceuticalDrugOrlistatForLeanMuscleGain99%Min96829-58-2OrlistatCASNumber:96829-58-2MolecularFormula:C29H53NO5MolecularWeight:495.73Density:0.976g/cm3MeltingPoint:<50ºCBoilingPoint:615.9ºCat760mmHgFlashPoint:326.3ºCSolubility:DMSO:19mg/mLinwaterAppearance:WhitecrystallinepowderDescription:Orlistat(alsoknownastetrahydrolipstatin)isadrugdesignedtotreatobesity.ItismarketedasaprescriptiondrugunderthetradenameXenicalbyRocheinmostcountries,andissoldover-the-counterasAllibyGlaxo***ithKlineintheUnitedKingdomandtheUnitedsprimaryfunctionispreventingtheabsorptionoffatsfromthehumandietbyactingasalipaseinhibitor,therebyreducingcaloricintake.Itisintendedforuseinconjunctionwithahealthcareprovider-supervisedreduced-caloriediet.Orlistatisthesaturatedderivativeoflipstatin,apotentnaturalinhibitorofpancreaticlipasesisolatedfromthebacteriumStreptomycesever,duetoitsrelativesimplicityandstability,orlistatwaschosenoverlipstatinfordevelopmentasananti-obesitydrug.Theeffectivenessoforlistatinpromotingweightlossisdefinite,thoughmodest.Pooleddatafromclinicaltrialssuggestthatpeoplegivenorlistatinadditiontolifestylemodificati***,suchasdietandexercise,loseabout2-3kilograms(4.4-6.6lb)morethanthosenottakingthedrugoverthecourseofayear.Orlistatalsomodestlyreducesbloodpressure,andappearstopreventthe***etoftype2diabetes,whetherduetoweightlossitselfortoothereffects;inalargerandomizedcontrolledtrial,orlistatwasfoundtoreducetheincidenceofdiabetesbynearly40%inobesepeople.Orlistatisnotoriousforitsgastrointestinalsideeffects(sometimesreferredtoastreatmenteffects),whichcanincludesteatorrhea(oily,loosestools).Thesedecreasewithtime,however,andarethemostfrequentlyreportedadverseeffectsofthetheUnitedStatesandtheEuropeanUnion,orlistatis***ailableforsalewithoutaprescription.Over-the-counterapprovalwascontroversialintheUnitedStates,withc***umeradvocacygroupPublicCitizenrepeatedlyopposingitonsafetyandefficacygrounds.Genericformulati***oforlistatare***ailableinsomecountries.InAustraliaitislistedasanS3medication,whichmeansit's***ailableoverthecounterinpharmacies.Attimes,suchasinspring2012,orlistathascomeintoshortsupply,withc***equentpriceincreasesbecauseofnon***ailabilityofoneofthedrug'scomponents.MedicalusesOrlistatisusedforthetreatmentofobesity.Theamountofweightlossachievedwithorlistatvaries.Inone-yearclinicaltrials,between35.5%and54.8%ofsubjectsachieveda5%orgreaterdecreaseinbodymass,althoughnotallofthismasswasnecessarilyfat.Between16.4%and24.8%achievedatleasta10%decreaseinbodyterorlistatwasstopped,asignificantnumberofsubjectsregainedweight-upto35%oftheweighttheyhadlost.Theincidenceoftype2diabetesinanobesepopulationoverfouryearsisdecreasedwithorlistat(6.2%)comparedtoplacebo(9.0%).Long-termuseoforlistatalsoleadstoamodestreductioninbloodpressure(meanreducti***of2.5and1.9mmHginsystolicanddiastolicbloodpressurerespectively).ProductNameOrlistatSynonyms(S)-2-FORMYLAMINO-4-METHYL-PENTANOICACID(S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]-DODECYLESTER;RO-18-0647;(-)-TETRAHYDROLIPSTATIN;N-FORMYL-L-LEUCINE(1S)-1-[[(2S,3S)-3-HEXYL-4-OXO-2-OXETANYL]METHYL]DODECYLESTER;XENICAL;(-)-Tetrahydrolipstatin(EquivalentToOrlistat);Orlipastat;(1S)-1-{[(2R,3S)-3-hexyl-4-oxooxetan-2-yl]methyl}dodecylN-formyl-D-leucinate;[(1S)-1-[[(2S)-3-hexyl-4-oxo-oxetan-2-yl]methyl]dodecyl](2S)-2-formamido-4-methyl-pentanoateMolecularFormulaC29H53NO5MolecularWeight495.7348InChIInChI=1/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25?,26-,27-/m0/s1CASRegistryNumber96829-58-2MolecularStructureDensity0.976g/cm3Boilingpoint615.9¡ãCat760mmHgRefractiveindex1.469Flashpoint326.3¡ãCVapourPressure4.23E-15mmHgat25¡ãCAssay99%AppearanceWhiteorwhitepowder3.COA:TESTSSpecificationeResultsDescriptionWhiteoralmostcrystallinepowderWhitecrystallinepowderIdentificationIRConformsSpecificrotation-33-35¡ã-34¡ãLossondrying<0.5%0.35%Meltingpoint42-45¡æ42-44¡æWater<=2.0%0.25%Residualsolventsn-hexane<=290ppmn-heptane<=5000ppm20ppm1260ppmAssay(HPLC)>=96.0%(ONDRYBASIS)97.4%)